診療科・部門

トップページ診療科・部門泌尿器科部研究実績

研究実績

令和5年6月改訂

原著論文

英文

  1. Kobayashi M, Narita S, Matsui Y, Kanda S, Hidaka Y, Abe H, Tsuzuki T, Ito K, Kojima T, Kato M, Hatakeyama S, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Morita S, Habuchi T, Ogawa O, Nishiyama H, Kitamura H, Kobayashi T; Japan Urological Oncology Group. Impact of histological variants on outcomes in patients with urothelial carcinoma treated with pembrolizumab: a propensity score matching analysis. BJU Int. 2022 ;130:226-234.
  2. Kobayashi T, Ito K, Kojima T, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Ogawa O, Kitamura H, Nishiyama H. Pre-pembrolizumab neutrophil-to-lymphocyte ratio (NLR) predicts the efficacy of second-line pembrolizumab treatment in urothelial cancer regardless of the pre-chemo NLR. Cancer Immunol Immunother. 2022;71:461-471.
  3. Nishiyama N, Kobayashi T, Narita S, Hidaka Y, Ito K, Maruyama S, Mukai S, Tsutsumi M, Miki J, Okuno T, Yoshio Y, Matsumoto H, Shimazui T, Segawa T, Karashima T, Masui K, Fukuta F, Tashiro K, Imai K, Suekane S, Nagasawa S, Higashi S, Fukui T, Kojima T, Morita S, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Efficacy and safety of pembrolizumab for older patients with chemoresistant urothelial carcinoma assessed using propensity score matching. J Geriatr Oncol. 2022;13:88-93.
  4. Tamada S, Kondoh C, Matsubara N, Mizuno R, Kimura G, Anai S, Tomita Y, Oyama M, Masumori N, Kojima T, Matsumoto H, Chen M, Li M, Matsuda K, Tanaka Y, Rini BI, Uemura H. Pembrolizumab plus axitinib versus sunitinib in metastatic renal cell carcinoma: outcomes of Japanese patients enrolled in the randomized, phase III, open-label KEYNOTE-426 study. Int J Clin Oncol. 2022;27:154-164.
  5. Tanaka K, Kandori S, Sakka S, Nitta S, Tanuma K, Shiga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Shimazui T, Watanabe M, Sato TA, Miyamoto T, Matsuzaka T, Shimano H, Nishiyama H. ELOVL2 promotes cancer progression by inhibiting cell apoptosis in renal cell carcinoma. Oncol Rep. 2022;47:23.
  6. Nishimura N, Miyake M, Iida K, Miyamoto T, Tomida R, Numakura K, Inokuchi J, Yoneyama T, Matsumura Y, Yajima S, Masuda H, Terada N, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Prognostication in Japanese patients with bacillus Calmette-Guérin-unresponsive non-muscle-invasive bladder cancer undergoing early radical cystectomy. Int J Urol. 2022;29:242-249.
  7. Kato R, Naito S, Numakura K, Hatakeyama S, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Ohyama C, Habuchi T, Tsuchiya N, Obara W. Significance of upfront cytoreductive nephrectomy stratified by IMDC risk for metastatic renal cell carcinoma in targeted therapy era – a multi-institutional retrospective study. Int J Clin Oncol. 2022;27:563-573.
  8. Nagumo Y, Onozawa M, Kojima T, Terada N, Shiota M, Mitsuzuka K, Yasumoto H, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Saito T, Yokomizo A, Kohei N, Tabata KI, Takahashi A, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H; Japanese Urological Oncology Group (JUOG). Efficacy of combined androgen blockade therapy in patients with metastatic hormone-sensitive prostate cancer stratified by tumor burden. Int J Urol. 2022;29:398-405.
  9. Akamatsu S, Terada N, Takata R, Kinoshita H, Shimatani K, Momozawa Y, Yamamoto M, Tada H, Kawamorita N, Narita S, Kato T, Nitta M, Kandori S, Koike Y, Inazawa J, Kimura T, Kimura H, Kojima T, Terachi T, Sugimoto M, Habuchi T, Arai Y, Yamamoto S, Matsuda T, Obara W, Kamoto T, Inoue T, Nakagawa H, Ogawa O. Clinical Utility of Germline Genetic Testing in Japanese Men Undergoing Prostate Biopsy. JNCI Cancer Spectr. 2022;6:pkac001.
  10. Tomida R, Miyake M, Minato R, Sawada Y, Matsumura M, Iida K, Hori S, Fukui S, Ohyama C, Miyake H, Hongo F, Taoka R, Kobayashi T, Kojima T, Matsui Y, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Hashine K; Japanese Urological Oncology Group. Impact of carcinoma in situ on the outcome of intravesical Bacillus Calmette-Guérin therapy for non-muscle-invasive bladder cancer: a comparative analysis of large real-world data. Int J Clin Oncol. 2022;27:958-968.
  11. Kita Y, Ito K, Sano T, Hashimoto K, Mochizuki T, Shiraishi Y, Araki H, Fujiwara M, Kanamaru S, Takahashi T, Hishiki K, Okada T, Ogawa K, Ito M, Kojima T, Nishiyama N, Matsui Y, Nishiyama H, Kitamura H, Kobayashi T. Clinical practice pattern in patients with advanced urothelial cancer who had progressed on pembrolizumab in the pre-enfortumab vedotin era. Int J Urol. 2022;29:647-655.
  12. Terada N, Aizawa R, Nihei K, Shiota M, Kojima T, Kimura T, Inoue T, Kitamura H, Sugimoto M, Nishiyama H, Mizowaki T, Kamoto T. Narrative review of local prostate and metastasis-directed radiotherapy in the treatment of metastatic prostate cancer. Jpn J  Clin Oncol. 2022;52:633-641.
  13. Numakura K, Nakai Y, Kojima T, Osawa T, Narita S, Nakayama M, Kitamura H, Nishiyama H, Shinohara N. Overview of clinical management for older patients with renal cell carcinoma. Jpn J Clin Oncol. 2022;52:665-681.
  14. Kawahara T, Kawai K, Kojima T, Nagumo Y, Sakka S, Kandori S, Negoro H, Mathis BJ, Maruo K, Miura K, Sakamoto N, Shinohara N, Yamashita S, Yonemori K, Kishida T, Ukimura O, Nishimura K, Kobayashi Y, Nishiyama H. Phase II trial of nivolumab monotherapy and biomarker screening in patients with chemo-refractory germ cell tumors. Int J Urol. 2022;29:741-747.
  15. Sekito S, Ogura Y, Soga N, Kojima T. Pre-operative Serum Albumin as a Potential Predictor of Benign Lesions in Renal Masses. Cancer Diagn Progn. 2022;2:345-350.
  16. Narita S, Terada N, Nomura K, Sakamoto S, Hatakeyama S, Kato T, Matsui Y, Inokuchi J, Yokomizo A, Tabata KI, Shiota M, Kimura T, Kojima T, Inoue T, Mizowaki T, Sugimoto M, Kitamura H, Kamoto T, Nishiyama H, Habuchi T; Japanese Urological Oncology Group. Cancer-specific and net overall survival in older patients with de novo metastatic prostate cancer initially treated with androgen deprivation therapy. Int J Urol. 2022;29:1147-1154.
  17. Nitta S, Kandori S, Tanaka K, Sakka S, Siga M, Nagumo Y, Negoro H, Kojima T, Mathis BJ, Shimazui T, Miyamoto T, Matsuzaka T, Shimano H, Nishiyama H. ELOVL5-mediated fatty acid elongation promotes cellular proliferation and invasion in renal cell carcinoma. Cancer Sci. 2022;113:2738-2752.
  18. Inoue T, Miyake M, Nishimura N, Onozawa M, Kashima S, Numakura K, Narita S, Iida K, Uemura M, Matsushita Y, Inokuchi J, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Habuchi T. Association of Increased Age With Decreased Response to Intravesical Instillation of Bacille Calmette-Guérin in Patients With High-Risk Non-Muscle Invasive Bladder Cancer: Retrospective Multi-Institute Results From the Japanese Urological Oncology Research Group JUOG-UC-1901-BCG.Urology. 2022;167:158-164.
  19. Murakami Y, Matsumoto K, Miyake M, Amano N, Shimura S, Nishimura N, Iida K, Matsushita Y, Abe T, Yamada T, Uemura M, Matsui Y, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Iwamura M. Real-world treatment patterns and oncological outcomes in early relapse and refractory disease after bacillus Calmette-Guérin failure in non-muscle-invasive bladder cancer. Int J Urol. 2022;29:1195-1203.
  20. Kojima T, Kato R, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Nakaigawa N, Sugino Y, Hamamoto S, Ito H, Murakami H, Obara W. Real-world effectiveness of nivolumab plus ipilimumab and second-line therapy in Japanese untreated patients with metastatic renal cell carcinoma: 2-year analysis from a multicenter retrospective clinical study (J-cardinal study). Jpn J Clin Oncol. 2022;52(11):1345-1352.
  21. Chihara I, Nagumo Y, Kandori S, Kojo K, Sano K, Hamada K, Tanuma K, Tsuchiya H, Shiga M, Sakka S, Kimura T, Kawahara T, Hoshi A, Negoro H, Kojima T, Bryan MJ, Okuyama A, Higashi T, Nishiyama H. Clinicopathological features of adrenal malignancies: Analysis of hospital-based cancer registry data in Japan. Int J Urol. 2022;29:1331-1337.
  22. Matsubara N, Yonese J, Kojima T, Azuma H, Matsumoto H, Powles T, Rosenberg JE, Petrylak DP, Matsangou M, Wu C, Campbell M, Yamashiro M. Japanese subgroup analysis of EV-301: An open-label, randomized phase 3 study to evaluate enfortumab vedotin versus chemotherapy in subjects with previously treated locally advanced or metastatic urothelial carcinoma. Cancer Med. 2023;12:2761-2771.
  23. Sobu R, Numakura K, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Clinical impact of early response to first-line VEGFR-TKI in patients with metastatic renal cell carcinoma on survival: A multi-institutional retrospective study. Cancer Med. 2023;12:4100-4109.
  24. Kageyama T, Soga N, Sekito S, Kato S, Ogura Y, Kojima T, Kanai M, Inoue T. Dramatic response to pembrolizumab after pseudoprogression in a patient with advanced metastatic castration-resistant prostate cancer. IJU Case Rep. 2022;5:442-445.
  25. Nishikawa R, Miyake M, Morizane S, Shimizu R, Teraoka S, Honda M, Iida K, Nishimura N, Sazuka T, Kimura T, Ito A, Shiga K, Taoka R, Kojima T, Kobayashi T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K, Takenaka A. C-reactive protein as a prognostic predictor for non-muscle invasive bladder cancer after intravesical bacillus Calmette-Guérin therapy: A Japan Urological Oncology Group study analysis. Int J Urol. 2023;30:299-307.
  26. Kato T, Matsubara N, Shiota M, Eto M, Osawa T, Abe T, Shinohara N, Yasumizu Y, Tanaka N, Oya M, Nishimoto K, Hayashi T, Nakayama M, Kojima T, Namikawa K, Fujisawa T, Okano S, Hida E, Nakamura Y, Bando H, Yoshino T, Nonomura N. IMAGENE trial: multicenter, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy of niraparib with PD-1 inhibitor in solid cancer patients with homologous recombination repair genes mutation. BMC Cancer. 2022;22:1292.
  27. Nagumo Y, Kandori S, Kojima T, Hamada K, Nitta S, Chihara I, Shiga M, Negoro H, Mathis BJ, Nishiyama H. Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma. Cancers (Basel). 2022;14:6207.
  28. Kato R, Kojima T, Sazuka T, Yamamoto H, Fukuda S, Yamana K, Sugino Y, Hamamoto S, Nakaigawa N, Kabu K, Murakami H, Obara W. A Multicentre Retrospective Study of Nivolumab Plus Ipilimumab for Untreated Metastatic Renal Cell Carcinoma. Anticancer Res. 2021;41: 6199-6209.
  29. Kato M, Kobayashi T, Matsui Y, Ito K, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Ozaki Y, Tashiro Y, Uegaki M, Kojima T, Uchida J, Ogawa O, Nishiyama H, Kitamura H; Japan Urological Oncology Group. Impact of the objective response to and number of cycles of platinum-based first-line chemotherapy for metastatic urothelial carcinoma on overall survival of patients treated with pembrolizumab. Int J Urol. 2021;28: 1261-1267.
  30. Okita K, Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. External validation of the REMARCC model for the selection of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma: A multicenter retrospective study. Urol Oncol. 2021;39: 836.e11-836.e17.
  31. Mizuno K, Sumiyoshi T, Okegawa T, Terada N, Ishitoya S, Miyazaki Y, Kojima T, Katayama H, Fujimoto N, Hatakeyama S, Shiota M, Yoshimura K, Matsui Y, Narita S, Matsumoto H, Kurahashi R, Kanno H, Ito K, Kimura H, Kamiyama Y, Sunada T, Goto T, Kobayashi T, Yamada H, Tsuchiya N, Kamba T, Matsuyama H, Habuchi T, Eto M, Ohyama C, Ito A, Nishiyama H, Okuno H, Kamoto T, Fujimoto A, Ogawa O, Akamatsu S. Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer. Clin Cancer Res. 2021;27: 6164-6173.
  32. Iida K, Miyake M, Murakami K, Komiyama M, Okajima E, Sazuka T, Nishiyama N, Yasumoto H, Kimura T, Ito A, Shiga K, Yamagishi A, Kikuchi H, Sugimoto M, Taoka R, Kobayashi T, Kojima T, Kitamura H, Nishiyama H, Fujimoto K. Bacillus Calmette-Guérin-unresponsive non-muscle invasive bladder cancer outcomes in patients without radical cystectomy. Int J Clin Oncol. 2021;26: 2104-2112.
  33. Numakura K, Muto Y, Naito S, Hatakeyama S, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Arai Y, Ito A, Nishiyama H, Kojima Y, Obara W, Ohyama C, Tsuchiya N, Habuchi T. Outcomes of axitinib versus sunitinib as first-line therapy to patients with metastatic renal cell carcinoma in the immune-oncology era. Cancer Med. 2021;10: 5839-5846.
  34. Kimura T, Kojo K, Shiga M, Chihara I, Ikeda A, Kandori S, Kojima T, Haruta J, Nishiyama H. Impact of Early Exposure to Simulation Program on Undergraduate Medical Students’ Interest in Urology. J Med Educ Curric Dev. 2021;8: 23821205211020750.
  35. Shiota M, Terada N, Kitamura H, Kojima T, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Sugimoto M, Mizowaki T, Kamoto T, Nishiyama H, Eto M; Japanese Urological Oncology Group. Novel metastatic burden-stratified risk model in de novo metastatic hormone-sensitive prostate cancer. Cancer Sci. 2021;112: 3616-3626.
  36. Nitta S, Kawai K, Kimura T, Kandori S, Kawahara T, Kojima T, Nishiyama H. Advanced germ cell tumor patients undergoing post-chemotherapy retroperitoneal lymph node dissection: Impact of residual teratoma on prognosis. Int J Urol. 2021;28: 840-847
  37. Miyake M, Nishimura N, Iida K, Fujii T, Nishikawa R, Teraoka S, Takenaka A, Kikuchi H, Abe T, Shinohara N, Okajima E, Shimizu T, Hori S, Tsuchiya N, Owari T, Murakami Y, Taoka R, Kobayashi T, Kojima T, Nishiyama N, Kitamura H, Nishiyama H, Fujimoto K. Intravesical Bacillus Calmette-Guérin Treatment for T1 High-Grade Non-Muscle Invasive Bladder Cancer with Divergent Differentiation or Variant Morphologies. Cancers (Basel). 2021;13: 2615.
  38. Shiga M, Nagumo Y, Chihara I, Nitta S, Kojo K, Kimura T, Kandori S, Kojima T, Okuyama A, Higashi T, Nishiyama H. Discrepancy between clinical and pathological T stages in upper urinary tract urothelial carcinoma: Analysis of the Hospital-Based Cancer Registry data in Japan. Int J Urol. 2021;28: 814-819.
  39. Yu EY, Petrylak DP, O’Donnell PH, Lee JL, van der Heijden MS, Loriot Y, Stein MN, Necchi A, Kojima T, Harrison MR, Hoon Park S, Quinn DI, Heath EI, Rosenberg JE, Steinberg J, Liang SY, Trowbridge J, Campbell M, McGregor B, Balar AV. Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial. Lancet Oncol. 2021;22: 872-882.
  40. Nagumo Y, Kandori S, Tanuma K, Nitta S, Chihara I, Shiga M, Hoshi A, Negoro H, Kojima T, Mathis BJ, Funakoshi Y, Nishiyama H. PLD1 promotes tumor invasion by regulation of MMP-13 expression via NF-κB signaling in bladder cancer. Cancer Lett. 2021;511: 15-25
  41. Ito K, Kobayashi T, Kojima T, Hikami K, Yamada T, Ogawa K, Nakamura K, Sassa N, Yokomizo A, Abe T, Tsuchihashi K, Tatarano S, Inokuchi J, Tomida R, Fujiwara M, Takahashi A, Matsumoto K, Shimizu K, Araki H, Kurahashi R, Osaki Y, Tashiro Y, Uegaki M, Ogawa O, Kitamura H, Nishiyama H. Pembrolizumab for treating advanced urothelial carcinoma in patients with impaired performance status: Analysis of a Japanese nationwide cohort. Cancer Med. 2021;10: 3188-3196.
  42. Miyake M, Iida K, Nishimura N, Miyamoto T, Fujimoto K, Tomida R, Matsumoto K, Numakura K, Inokuchi J, Morizane S, Yoneyama T, Matsumura Y, Abe T, Inoue M, Yamada T, Terada N, Hirao S, Uemura M, Matsushita Y, Taoka R, Kobayashi T, Kojima T, Matsui Y, Kitamura H, Nishiyama H; Japanese Urological Oncology Group. Non-maintenance intravesical Bacillus Calmette-Guérin induction therapy with eight doses in patients with high- or highest-risk non-muscle invasive bladder cancer: a retrospective non-randomized comparative study. BMC Cancer. 2021;21: 266.
  43. Sekino Y, Ishikawa H, Kimura T, Kojima T, Maruo K, Azuma H, Yoshida K, Kageyama Y, Ushijima H, Tsuzuki T, Sakurai H, Nishiyama H. Bladder preservation therapy in combination with atezolizumab and radiation therapy for invasive bladder cancer (BPT-ART) – A study protocol for an open-label, phase II, multicenter study. Contemp Clin Trials Commun. 2021;21: 100724.
  44. Shiga M, Miyazaki J, Tanuma K, Nagumo Y, Yoshino T, Kandori S, Negoro H, Kojima T, Tanaka R, Okiyama N, Fujisawa Y, Watanabe M, Yamasaki S, Kiyohara H, Watanabe M, Sato TA, Tahara H, Nishiyama H, Yano I. The liposome of trehalose dimycolate extracted from M. bovis BCG induces antitumor immunity via the activation of dendritic cells and CD8+ T cells. Cancer Immunol Immunother. 2021;70: 2529-2543.
  45. Nakai Y, Takeuchi A, Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Minami K, Ueda K, Ozawa M, Uemura M, Miyauchi Y, Ohba K, Kashiwagi A, Murakami M, Sazuka T, Yasumoto H, Morizane S, Kawasaki Y, Morooka D, Shimazui T, Yamamoto Y, Nakagomi H, Tomida R, Ito YM, Murai S, Kitamura H, Nishiyama H, Shinohara N; Japanese Urological Oncology Group. Efficacy and safety of second-line axitinib in octogenarians with metastatic renal cell carcinoma. J Geriatr Oncol. 2021;12: 834-837.
  46. Hatakeyama S, Naito S, Numakura K, Kato R, Koguchi T, Kojima T, Kawasaki Y, Kandori S, Kawamura S, Tsushima E, Nishiyama H, Ito A, Kojima Y, Habuchi T, Obara W, Tsuchiya N, Ohyama C. Impact of cytoreductive nephrectomy in patients with primary metastatic renal cell carcinoma receiving systemic tyrosine kinase inhibitor therapy: A multicenter retrospective study. Int J Urol. 2021;28: 369-375.
  47. Junichi Inokuchi, Kentaro Kuroiwa, Hiroyuki Nishiyama, Takahiro Kojima, Yoshiyuki Kakehi, Mikio Sugimoto, Atsushi Takenaka, Kiyohide Fujimoto, Tohru Nakagawa, Tomonori Habuchi, Katsuyoshi Hashine, Junki Mizusawa, Junko Eba, Seiji Naito, on behalf of the Urologic Oncology Study Group of the Japan Clinical Oncology Group (JCOG) Significance of the Timing of Ureteral Ligation during Radical Nephroureterectomy for Upper Urinary Tract Urothelial Cancer on Subsequent Intravesical Recurrence and Prognosis Int J Urol. 2021 28:208-214.
  48. Kobayashi T, Ito K, Kojima T, Kato M, Kanda S, Hatakeyama S, Matsui Y, Matsushita Y, Naito S, Shiga M, Miyake M, Muro Y, Nakanishi S, Kato Y, Shibuya T, Hayashi T, Yasumoto H, Yoshida T, Uemura M, Taoka R, Kamiyama M, Ogawa O, Kitamura H, Nishiyama H; Japan Urological Oncology Group. Risk stratification for the prognosis of patients with chemoresistant urothelial cancer treated with pembrolizumab. Cancer Sci. 2021;112: 760-773.
  49. Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, Nishiyama H. Prognostic impact of non-urothelial carcinoma of the upper urinary tract: Analysis of hospital-based cancer registry data in Japan. Int J Urol. 2021;28: 54-60.
  50. Shiota M, Terada N, Saito T, Yokomizo A, Kohei N, Goto T, Kawamura S, Hashimoto Y, Takahashi A, Kimura T, Tabata KI, Tomida R, Hashimoto K, Sakurai T, Shimazui T, Sakamoto S, Kamiyama M, Tanaka N, Mitsuzuka K, Kato T, Narita S, Yasumoto H, Teraoka S, Kato M, Osawa T, Nagumo Y, Matsumoto H, Enokida H, Sugiyama T, Kuroiwa K, Inoue T, Mizowaki T, Kamoto T, Kojima T, Kitamura H, Sugimoto M, Nishiyama H, Eto M; Japanese Urological Oncology Group (JUOG). Differential prognostic factors in low- and high-burden de novo metastatic hormone-sensitive prostate cancer patients. Cancer Sci. 2021;112: 1524-1533.
  51. Ikeda A, Nosato H, Kochi Y, Negoro H, Kojima T, Sakanashi H, Murakawa M, Nishiyama H. Cystoscopic Imaging for Bladder Cancer Detection Based on Stepwise Organic Transfer Learning with a Pretrained Convolutional Neural Network. J Endourol. 2021;35: 1030-1035.
  52. Mori K, Obata-Yasuoka M, Saida T, Nishida K, Takahashi H, Hosokawa Y, Takei Y, Tsumagari A, Yoshida M, Kimura Y, Abe T, Tsukuda Y, Harada S, Kojima T, Minami M. Pelvic arterial embolisation with cyanoacrylate during caesarean hysterectomy for placenta accreta. Minim Invasive Ther Allied Technol. 9:1-8.2020.
  53. Kitamura H, Hinotsu S, Tsukamoto T, Shibata T, Mizusawa J, Kobayashi T, Miyake M, Nishiyama N, Kojima T, Nishiyama H; Urologic Oncology Study Group of the Japan Clinical Oncology Group. Effect of neoadjuvant chemotherapy on health-related quality of life in patients with muscle-invasive bladder cancer: results from JCOG0209, a randomized phase III study. Jpn J Clin Oncol. 2020 16;50: 1464-1469.
  54. Kojo K, Kawai K, Kawahara T, Kimura T, Kandori S, Nagumo Y, Nitta S, Kojima T, Okuyama A, Higashi T, Nishiyama H. Recent malignant testicular tumor trend in Japan, a country with an aging population: a large-scale study of 2012-2015 hospital-based cancer registry data. Jpn J Clin Oncol. 28;50: 1201-1208.2020
  55. Nagumo Y, Kawai K, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Okuyama A, Higashi T, Nishiyama H. Prognostic significance of non-urothelial carcinoma of bladder: analysis of nationwide hospital-based cancer registry data in Japan. Jpn J Clin Oncol. 5;50: 1068-1075.2020
  56. Kimura T, Kawai K, Kandori S, Nitta S, Kojo K, Nagumo Y, Negoro H, Okuyama A, Higashi T, Kojima T, Nishiyama H. Impact of centralization in primary retroperitoneal sarcoma treatment: analysis using hospital-based cancer registry data in Japan. Int J Clin Oncol. 25(9):1687-1694.2020
  57. Osawa T, Kojima T, Hara T, Sugimoto M, Eto M, Takeuchi A, Minami K, Nakai Y, Ueda K, Shinohara N; Japanese Urological Oncology Group. Oncological outcomes of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. Cancer Sci. 111(7):2460-2471.2020
  58. Tanaka K, Kandori S, Nitta S, Chihara I, Kojo K, Nagumo Y, Kimura T, Kojima T, Kawai K, Okuyama A, Higashi T, Nishiyama H. Characteristics of penile cancer in Japan: An analysis of nationwide hospital-based cancer registry data. Int J Urol. 27(6):538-542.2020
  59. Ikeda A, Kojima T, Kawai K, Hinotsu S, Keino N, Shiga K, Miyake H, Miyata Y, Enomoto Y, Shimizu F, Anai S, Matsuyama H, Suzuki C, Kanimoto Y, Shigeta K, Naito S, Akaza H, Nishiyama H. Risk for intravesical recurrence of bladder cancer stratified by the results on two consecutive UroVysion fluorescence in situ hybridization tests: a prospective follow-up study in Japan. Int J Clin Oncol. 25(6):1163-1169.2020
  60. Nitta S, Kawai K, Kimura T, Kawahara T, Kandori S, Hoshi A, Kojima T, Nishiyama H. Predictors of venous thromboembolism development before and during chemotherapy for advanced germ cell tumor. Jpn J Clin Oncol. 9;50:338-343.2020
  61. Ikeda A, Nosato H, Kochi Y, Kojima T, Kawai K, Sakanashi H, Murakawa M, Nishiyama H. Support System of Cystoscopic Diagnosis for Bladder Cancer Based on Artificial Intelligence. J Endourol. 34(3):352-358.2020
  62. Nagumo Y, Kojima T, Shiga M, Kojo K, Tanaka K, Kandori S, Kimura T, Kawahara T, Kawai K, Okuyama A, Higashi T, Nishiyama H. Clinicopathological features of malignant urachal tumor: A hospital-based cancer registry data in Japan. Int J Urol. Int J Urol. 27(2):157-162.2020
  63. Nagumo Y, Kojima T, Shiga M, Kandori S, Kimura T, Takaoka EI, Onozawa M, Miyazaki J, Kawai K, Ishikawa H, Sakurai H, Nishiyama H. A single-institute experience of trimodal bladder-preserving therapy for histologic variants of urothelial carcinoma. Int J Clin Oncol. 25(2):354-361.2020.

和文

  1. 田中 隆造, 星 昭夫, 山口 茜, 野中 遥奈, 新田 聡, 古城 公佑, 南雲 義之, 池田 篤史, 松岡 妙子, 木村 友和, 神鳥 周也, 和久 夏井, 根来 宏光, 小島 崇宏, 河合 弘二, 西山 博之　後腹膜鏡下手術にて摘除した横隔膜原発気管支原生嚢胞の1例 泌尿器科紀要(0018-1994)66巻9号 Page307-311(2020.09)
  2. 濱田 和希, 石塚 竜太郎, 河合 弘二, 志賀 正宣, 田中 健, 池田 篤史, 吉野 喬之, 河原 貴史, 神鳥 周也, 木村 友和, 和久 夏衣, 星 昭夫, 小島 崇宏, 常樂 晃, 佐藤 泰樹, 須摩 桜子, 坂田 麻実子, 小原 直, 伊藤 孝美, 西山 博之　腎盂尿管壁の著明な肥厚を示したMucosa-associated lymphoid tissue(MALT)リンパ腫の1例　泌尿器科紀要(0018-1994)64巻12号 Page489-495(2018.12)
  3. 佐野 啓介, 木村 友和, 河合 弘二, 池田 篤史, 石塚 竜太郎, 神鳥 周也, 和久 夏衣, 星 昭夫, 小島 崇宏, 常樂 晃, 橋本 諒典, 西山 博之　異時性にマントル細胞リンパ腫を発症した病期Iセミノーマの1例　泌尿器科紀要(0018-1994)64巻12号 Page509-513(2018.12)
  4. 中川徹,菊地栄次,古家琢也,小島崇宏,田村啓多,三宅牧人,松井喜之,川井禎久,木村友和,横溝晃,永原啓,小林恭,家田健史,土屋邦彦,藤本清秀,西山博之 筋層非浸潤性膀胱癌の治療の実情についての本邦多施設アンケート調査結果. 泌尿器外科. 31(5), 557-564, 2018
  5. 内田 将央, 河合 弘二, 黒部 匡広, 池田 篤史, 神鳥 周也, 遠藤 剛, 宮川 友明, 小島 崇宏, 堤 雅一, 西山 博之. 栄養膜細胞への分化を伴った尿路上皮癌の多発転移に対し,ゲムシタビン,オキサリプラチン併用療法が奏効した1例. 泌尿器科紀要. 64(2),55-61, 2018

総説

英文

  1. Kimura T, Ishikawa H, Kojima T, Kandori S, Kawahara T, Sekino Y, Sakurai H, Nishiyama H. Bladder preservation therapy for muscle invasive bladder cancer: the past, present and future. Jpn J Clin Oncol. 28;50:1097-1107. 2020
  2. Osawa T, Takeuchi A, Kojima T, Shinohara N, Eto M, Nishiyama H. Overview of current and future systemic therapy for metastatic renal cell carcinoma. Jpn J Clin Oncol. 1;49:395-403.2019

和文

  1. 小島 崇宏, 西山 博之 尿路上皮がんに対する治療戦略：免疫チェックポイント阻害薬、分子標的薬の選択 腫瘍内科(1881-6568)Vol26.No4 Page377-383(2020.10)
  2. 新田 聡, 小島 崇宏, 岡田 奈緒美, 名雪 真季【疾患別　泌尿器科の薬物療法と患者管理　医師・看護師・薬剤師でつくる治療戦略】(第1章)泌尿器がん・腫瘍　精巣腫瘍Uro-Lo: 泌尿器Care & Cure(2189-8545)別冊 疾患別泌尿器科の薬物療法と患者管理 Page72-82(2020.05)
  3. 小島 崇宏【ここが変わった!膀胱癌診療-新ガイドラインを読み解く】遺伝子検査　ウロビジョン 臨床泌尿器科(0385-2393)74巻5号 Page298-300(2020.04)
  4. 小島 崇宏 NMIBCの診断に求められる新規尿中マーカーとその臨床応用への展望　筋層非浸潤性膀胱癌の再発予測におけるウロビジョンの意義について 泌尿器外科(0914-6180)33巻4号 Page385-388(2020.04)
  5. 新田 聡, 小島 崇宏【泌尿器科診療の最新スタンダード-平成の常識は令和の非常識】腫瘍　部位別　精巣腫瘍　薬物治療 臨床泌尿器科(0385-2393)74巻4号 Page090-092(2020.04)
  6. 小島 崇宏, 石川 仁, 西山 博之 膀胱温存療法の現況と将来展望 尿路悪性腫瘍研究会記録46巻 Page30-34(2020.04)
  7. 南雲 義之, 小島 崇宏, 西山 博之【希少癌に備える-いざという時のための基礎知識】Variantタイプ膀胱癌 臨床泌尿器科(0385-2393)73巻11号 Page842-845(2019.10)
  8. 新田 聡, 小島 崇宏 泌尿器科のスペシャリストを目指す人のための医師とナースの合同カンファレンス(第22回)　転移性精巣腫瘍に対して集学的治療を行った症例の巻 Uro-Lo: 泌尿器Care & Cure(2189-8545)24巻4号 Page486-491(2019.08)
  9. 小島 崇宏, 池田 篤史, 西山 博之 ウロビジョンを用いたNMIBCの新たなフォローアップ戦略 泌尿器外科(0914-6180)32巻4号 Page400-403(2019.04)
  10. 小島 崇宏, 西山 博之. 泌尿器癌における免疫チェックポイント阻害薬の現況.別冊医学のあゆみ がん免疫療法の躍進. 97-102頁,2018
  11. 小島崇宏, 池田篤史, 西山博之. 風雲！膀胱がんの診断・治療ウロビジョンDNA FISHプローブキット-TUR後フォローアップはどう変わるのか？ 泌尿器外科.Vlo.31 No.9,1275-1280,2018
  12. 小島崇宏, 池田篤史, 西山博之. ウロビジョンを用いたNMIBCの新たなフォローアップ戦略.臨床泌尿器科.72巻7号,501-506頁,2018
  13. 1小島崇宏, 池田篤史, 西山博之. シンポジウム5 NMIBCの治療戦略─新規技術導入による将来像─ウロビジョンを用いたNMIBC の新たなフォローアップ戦略 泌尿器外科.Vol31,667-669頁,2018
  14. 小島 崇宏. 特集 まるごと 泌尿器科手術・周術期管理に役立つ解剖と生理 ; 膀胱・尿道.泌尿器Care & Cure Uro-Lo誌.23巻2号,175-179頁,2018
  15. 小島崇宏. がん薬物療法の副作用 : 腎癌 : 分子標的薬・免疫チェックポイント阻害薬特集 この1冊で安心! 泌尿器科当直医マニュアル : 外来編 臨床泌尿器科　72巻3号273-278頁,2018

著書

  1. 小島崇宏, 西山博之. ガイドライン外来診療2019　膀胱癌.日経メディカル開発/ 604-607頁,2019
  2. 小島崇宏, 神鳥周也, 西山博之. 泌尿器癌におけるプレシジョン・メディシンの現状 プレシジョン・メディシン.　エヌ・ティー・エス刊.　2201-2209頁,2018

学会発表（特別講演・シンポジウム・ワークショップ・症例報告）

  1. 小島崇宏 ウロビジョンを用いたNMIBCの新たなフォローアップ戦略　第108回日本泌尿器科学会総会（神戸）12月，2020　シンポジウム
  2. 小島崇宏、新田聡、河原貴史、河合弘二、西山博之 症例から考える化学療法-3rd lineの選択について-日本泌尿器腫瘍学会第6回学術集会（京都）10月，2020 パネルディスカッション
  3. 関戸翔、小倉友二、曽我倫久人　当科における腎腫瘍に対するロボット支援下腎部分切除術の有用性の検討　第34回泌尿器内視鏡学会総会（岡山）　11月、2020
  4. 関戸翔、小倉友二、曽我倫久人、景山拓海　内分泌併用放射線治療後に神経内分泌化をきたした前立腺癌に対して化学療法が奏功した1例　第285回日本泌尿器科学会東海地方会　12月、2020
  5. 小島崇宏　腎尿管全摘除術における新展開　第33回日本泌尿器科内視鏡学会総会（京都）11月,2019　シンポジウム
  6. 小島崇宏　筋層非浸潤性膀胱癌の再発予測におけるウロビジョンの意義について 第12回ＢＣＧ注入療法研究会（東京）11月,2019　シンポジウム
  7. 小島崇宏、石川　仁、西山博之 膀胱温存療法の現況と将来展望 第46回尿路悪性腫瘍研究会「浸潤性膀胱癌に対する最近の進歩」2019年7月
  8. 小島崇宏、池田篤史、西山博之.　ウロビジョンを用いたNMIBCの新たなフォローアップ戦略　第11回ＢＣＧ注入療法研究会（東京）11月,2018　特別講演
  9. 小島崇宏、河合弘二、西山博之.　AYA世代の泌尿器科癌を考える AYA世代における泌尿器癌の現状と課題　胚細胞腫瘍を中心として　第106回日本泌尿器科学会総会（京都）4月，2018　シンポジウム
  10. 小島崇宏、木村友和、西山博之.　尿路上皮癌における免疫療法の現状と展望　第83回日本泌尿器科学会東部総会（東京）10月,2018　シンポジウム
  11. 小島崇宏、横隔膜脚後腔リンパ節転移を含む郭清術 第36回泌尿器科?術研究会（宮崎）1月,2018シンポジウム
  12. Takahiro Kojima.　Urology beyond Europe Tri-modality treatment of muscle-invasive bladder cancer　Joint Session of EAU and JUA　EAU(Copenhagen) 2018
  13. Takahiro Kojima. Treatment outcomes of advanced urothelial cancer treated with second-line chemotherapy in Japan East Asia Urologic Oncology Group Symposium (Korea) 2018

競争的研究費

文部科学省科研費研究実績

研究代表
  1. 泌尿器癌における全血RNAを用いた免疫細胞の多様性の理解と治療効果予測への応用
    研究代表者　小島崇宏
    研究期間（年度）2021-2023　基盤研究（C）
  2. 遺伝および環境要因を考慮した尿路上皮癌における新たな分子基盤の構築
    研究代表者　小島崇宏
    研究期間（年度）2018-2020　基盤研究（C）
研究分担
  1. アデノシン受容体シグナルに着目した低活動膀胱の病態生理解明と新規治療法の開発 研究代表者 高岡 栄一郎 研究期間（年度）2020-2022　基盤研究（C）
  2. 膀胱がんにおける脂肪酸の質の意義の解明：脂肪酸伸長酵素ELOVL6に着目して 研究代表者 松坂 賢 研究期間（年度）2020-2021　挑戦的研究（萌芽）
  3. 膀胱癌再発抑制のための癌抑制性ペプチド膀胱注入の効果と毒性の検討 研究代表者 島居 徹 研究期間（年度）2019-2021　基盤研究（C）
  4. クラスターCTCに注目した泌尿器癌の分子基盤に基づいたバイオマーカーの開発 研究代表者 松岡 妙子 研究期間（年度）2019-2021　基盤研究（C）
  5. 抗酸菌表層糖脂質をリード化合物とする新規癌免疫治療法の開発 研究代表者 西山 博之 研究期間 （年度）2018-2021　基盤研究（B）
  6. 骨格筋間質由来幹細胞移植による膀胱機能障害に対する新治療法の開発 研究代表者 星 昭夫 研究期間 （年度）2018-2020　基盤研究（C）
  7. 固形がんにおける体細胞変異のある炎症細胞によるがん発症支持機構の解明 研究代表者 坂田 麻実子 研究期間（年度）2018-2019 挑戦的研究（萌芽）
  8. ASIC/ ENaC を介した膀胱癌の発癌と浸潤機序の解明 研究代表者 西山 博之 研究期間（年度）2018-2020　挑戦的研究（萌芽）